-
Published on Oct 10, 2016
Widecells Group (LON:WDC) chief executive João Andrade expects the firm’s stem
cell insurance plan, CellPlan, to generate its first sales and revenues
within a matter of months.
Andrade tells Proactive Investors that everything is almost in place behind-the-scenes and is targeting first sales and revenues in early next year.
“We have now established our back office and everything should be operational in around 30 to 45 days,” Andrade tells Proactive.
“Following that, we’re expecting to start generating revenues and entering into sales at the beginning of next year.”
Andrade also calls the stem cell industry “exciting” and reckons it’s about to “go into the mainstream”.
Andrade also explains to Proactive that the company’s recent tie-up with the University of Westminster is part of its drive to raise awareness about the benefits of stem cell therapy.
“A partnership with a university to develop short stem cell e-learning courses for healthcare professionals is crucial for us to be able to raise awareness.”
http://www.4-traders.com/WIDECELLS-GROUP-PLC-30353180/
www.widecellsgroup.com/
Update on CellPlan - An Innovative Stem Cell Insurance Planhttps://t.co/jz3sbN6UoU#WDC pic.twitter.com/gYzdmQaum8— WideCells Group (@WideCells_Group) October 10, 2016
Our CSO Dr Peter Hollands is going to speaking at Conference and Exhibition on Cell and Gene Therapy Madridhttps://t.co/IuSIM0acvF pic.twitter.com/iTJkMqYn6u— WideCells Group (@WideCells_Group) October 4, 2016
No comments:
Post a Comment